Axsome Therapeutics Q2 2024 Adj. EPS $(1.12) Beats $(1.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics (NASDAQ:AXSM) reported a Q2 2024 adjusted EPS of $(1.12), beating the analyst consensus estimate of $(1.34) by 16.42%.
August 05, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics reported a Q2 2024 adjusted EPS of $(1.12), beating the analyst consensus estimate of $(1.34) by 16.42%. This positive earnings surprise is likely to have a favorable short-term impact on the stock price.
The better-than-expected EPS indicates that the company is performing better than analysts anticipated, which is generally a positive signal for investors. This is likely to result in a short-term increase in the stock price as market participants react to the positive news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100